Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Review of the Emerging Evidence
Authors:
- Alessandra BoniABAlessandra Boni
- Chiara VassalloCVChiara Vassallo
- Fabiana CicirielloFabiana Ciciriello
- Luca CristianiLCLuca Cristiani
- Alessandro ManciniAMAlessandro Mancini
- Luigi ZucaroLZLuigi Zucaro
- Sonia GrazianoSGSonia Graziano
- Bianca Maria GoffredoBGBianca Maria Goffredo
- Federico AlghisiFAFederico Alghisi
- Massimiliano RaponiMRMassimiliano Raponi
- Isabella FabiettiIFIsabella Fabietti
Preprint
- 25 February 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastro-intestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in-utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Ten relevant studies were identified and quali-tatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing con-firmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated im-provement in bowel dilatation and hyperchogenity. The infant was delivered at 36 +2, passed meconium spontane-ously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence early trajectory of CF, potentially by preventing MI and preserve pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.Keywords
All Related Versions
- Version 1, 2026-02-25, Preprints
- Published version: Journal of Clinical Medicine, 15 (7), 2625.
This publication has 20 references indexed in Scilit:
- Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic ModelsClinical Pharmacology & Therapeutics, 2025
- First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF studyJournal of Cystic Fibrosis, 2025
- CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful caseJournal of Cystic Fibrosis, 2025
- Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosisJournal of Cystic Fibrosis, 2024
- Clinical outcomes of two infants with cystic fibrosis, including presence of the vas deferens, born to a woman with cystic fibrosis taking CFTR modulators during both pregnanciesJournal of Cystic Fibrosis, 2024
- A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetusJournal of Cystic Fibrosis, 2022
- Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancyJournal of Cystic Fibrosis, 2021
- Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactationJournal of Cystic Fibrosis, 2021
- Meconium ileus in Cystic FibrosisJournal of Cystic Fibrosis, 2017
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006